ORBIS Corporation, a provider of reusable packaging solutions within the pharma space, has acquired Robinson Industries, a manufacturer of reusable plastic pallets and other products.¹

Although terms of the detail are yet to be disclosed, the move develops ORBIS’ manufacturing prowess, while allowing the company to operate at a faster production timeline. Robinson Industries—including 100 of its employees—will be switching over to the ORBIS brand, so the customer experience will not be impacted.

What thermoforming and manufacturing expertise does Robinson Industries bring to ORBIS?

Robinson Industries offers decades of experience in thermoforming that spans single- and twin-sheet processes, along with sheet extrusion and structural foam injection molding. Its product portfolio includes custom pallets, lids, and trays.

“Robinson Industries’ legacy of innovation and technical excellence aligns with ORBIS’ vision to transform supply chains through reusable packaging,” commented Norm Kukuk, president of ORBIS Corporation. “By combining our strengths, we will accelerate design innovation, deliver faster solutions, and help customers achieve greater sustainability and efficiency.”

How will the ORBIS–Robinson deal benefit packaging design and production timelines?

Customers will be able to take advantage of end-to-end thermoforming processes, which have the potential for faster design and prototyping, greater quality control, and a boost in innovation across ORBIS’ packaging portfolio.

“Robinson shares ORBIS’ deep commitment to customers, employees and the communities we serve,” added Kukuk. “This strong cultural alignment will drive a smooth integration and reinforce our shared focus on delivering exceptional value.”

Why is Morris & Dickson acquiring Prodigy Health?

Along the avenue of supply chain news, Morris & Dickson (M&D), an independent wholesale and specialty pharma distributor, has officially acquired Prodigy Health, a fellow specialty pharmaceutical distribution and services company. An original letter of intent for the acquisition was signed in December 2025.

Prodigy Health will now begin to operate as ProdigyMD.

The deal reportedly strengthens Morris & Dickson’s specialty portfolio and broadens access to plasma-derived therapies, while maintaining continuity, regulatory compliance, and uninterrupted service for healthcare providers across the US.

How does the Prodigy Health deal expand specialty and plasma therapy distribution?

As a result of the acquisition, M&D also expands its ability to better serve hospitals, specialty pharmacies, clinics, infusion centers, and alternate sites of care as demand for specialty and plasma therapies continues to rise. For manufacturers, the combined organization offers a larger independent distribution network with greater reach, specialty expertise, and a compliance-driven operating model.

“This transaction reflects our long-term commitment to specialty distribution and alternative sites of care,” said Jody Hatcher, CEO of Morris & Dickson. “Our focus is on expanding access to critical therapies while preserving continuity for customers and operating with regulatory integrity that is consistent with our independent, customer-first values.”

What will integration look like for Morris & Dickson and ProdigyMD?

According to the company release,² M&D is expected to begin a “phased integration process” powered by industry practices that abide by regulatory requirements. The goal is for customers and manufacturers to be able to benefit from the advantages of both parties without losing out on any advantages.

Emphasizing the strategic importance of the acquisition, Layne Martin, M&D’s head of specialty, highlighted how the move strengthens the company’s specialty capabilities and customer support model.

“This is a meaningful step forward in our specialty strategy,” he said. “By bringing Prodigy Health’s purpose-built plasma and specialty expertise into the Morris & Dickson family, we are strengthening our ability to support complex therapies while maintaining the service and compliance our customers expect. Our immediate focus is disciplined execution and personalized customer support.”

References

1. ORBIS Strengthens Manufacturing Portfolio with Acquisition of Robinson Industries. ORBIS. February 2, 2026. Accessed February 3, 2026. https://www.orbiscorporation.com/en-us/news/orbis-acquires-robinson-industries/

2. Morris & Dickson Completes Transaction to Acquire Prodigy Health. Morris & Dickson. January 26, 2026. Accessed February 3, 2026. https://www.morrisdickson.com/2026/01/26/morris-dickson-completes-transaction-to-acquire-prodigy-health/